Merck's Keytruda QLEX approved in Japan for subcutaneous use

Japan's health ministry has approved Merck & Co.'s subcutaneous Keytruda QLEX (KEYTRUDA) for all approved Keytruda indications in Japan. The product, to be marketed as Keyject, can be administered in 1 minute every 3 weeks or 2 minutes every 6 weeks.